A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers.
Thromb Res
; 34(1): 65-74, 1984 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-6729769
ABSTRACT
In a double-blind study on healthy subjects who underwent three 3-week periods of treatment with metoprolol (M) + sulfinpyrazone (S), M + placebo, and S + placebo, pharmacokinetics and plasma levels of M were not affected by concurrent administration of S. Analysis of variance change-over demonstrated a significant difference between treatments only for serum uric acid levels. Analysis of post-treatment and baseline data within each treatment showed decreased platelet count by M, lowered serum 6-keto PGF1 alpha by all three treatments, decreased serum TXB2 generation and arachidonic acid-induced platelet aggregation by S + M. No negative interaction between S + M was found.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Plaquetas
/
Sulfimpirazona
/
Metoprolol
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thromb Res
Ano de publicação:
1984
Tipo de documento:
Article